(Total Views: 651)
Posted On: 07/20/2020 11:32:27 AM
Post# of 148949
RE: CCR5 receptor occupancy test and IncellDX license agreement
Note that Cytodyn signed a worldwide license agreement with IncellDX in July 2019 granting them exclusive rights to PRO 140 (Leronlimab) for use in the development and commercialization of immunoassays for quantitative measurement of CCR5 levels on human cells.
https://www.cytodyn.com/investors/news-events...-agreement
More details on the corporate positioning strategies behind the agreement were published here:
https://www.ddn-news.com/index.php?newsarticle=13639
Note that Cytodyn signed a worldwide license agreement with IncellDX in July 2019 granting them exclusive rights to PRO 140 (Leronlimab) for use in the development and commercialization of immunoassays for quantitative measurement of CCR5 levels on human cells.
https://www.cytodyn.com/investors/news-events...-agreement
More details on the corporate positioning strategies behind the agreement were published here:
https://www.ddn-news.com/index.php?newsarticle=13639
(1)
(0)Scroll down for more posts ▼
